Tags

Type your tag names separated by a space and hit enter

Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
Int J Antimicrob Agents. 2004 Aug; 24(2):111-8.IJ

Abstract

Originating from 25 selected intensive care units (ICUs) in North America, a total of 1,321 bacterial strains from blood, respiratory tract, urine and wound sites were processed at a central laboratory as part of the SENTRY Antimicrobial Surveillance Program (2001) to assess their occurrence rates and antimicrobial susceptibility profiles. The rank order of pathogens recovered was Staphylococcus aureus (24.1%), Pseudomonas aeruginosa (12.2%), Escherichia coli (10.1%), Klebsiella spp. (8.9%), Enterococcus spp. (7.2%), coagulase-negative staphylococci (7.0%) and Enterobacter spp. (7.0%). Although oxacillin resistance among S. aureus was 51.4%, no resistance was detected to vancomycin, linezolid and quinupristin/dalfopristin. The most active agents tested against P. aeruginosa were amikacin, cefepime, tobramycin, meropenem and piperacillin/tazobactam (3.1-13.0% resistance). Among agents tested against the Enterobacteriaceae, amikacin, cefepime, imipenem and meropenem showed greatest in vitro activity (0.0-3.4% resistance). Extended-spectrum beta-lactamase-producing phenotype rates were 11.2 and 16.2% in E. coli and Klebsiella spp., respectively. Linezolid was most active against enterococci (1.1% resistance; G2576U ribosomal mutation) whereas 28.4% of isolates were resistant to vancomycin. Cefepime and the carbapenems (imipenem or meropenem) for Gram-negative isolates and linezolid for Gram-positive isolates, provided the broadest spectrum of in vitro activity against contemporary ICU pathogens in North America.

Authors+Show Affiliations

The JONES Group/JMI Laboratories Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IW 52317, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15288308

Citation

Streit, Jennifer M., et al. "Assessment of Pathogen Occurrences and Resistance Profiles Among Infected Patients in the Intensive Care Unit: Report From the SENTRY Antimicrobial Surveillance Program (North America, 2001)." International Journal of Antimicrobial Agents, vol. 24, no. 2, 2004, pp. 111-8.
Streit JM, Jones RN, Sader HS, et al. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents. 2004;24(2):111-8.
Streit, J. M., Jones, R. N., Sader, H. S., & Fritsche, T. R. (2004). Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). International Journal of Antimicrobial Agents, 24(2), 111-8.
Streit JM, et al. Assessment of Pathogen Occurrences and Resistance Profiles Among Infected Patients in the Intensive Care Unit: Report From the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents. 2004;24(2):111-8. PubMed PMID: 15288308.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). AU - Streit,Jennifer M, AU - Jones,Ronald N, AU - Sader,Helio S, AU - Fritsche,Thomas R, PY - 2003/11/17/received PY - 2003/12/12/accepted PY - 2004/8/4/pubmed PY - 2004/10/22/medline PY - 2004/8/4/entrez SP - 111 EP - 8 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 24 IS - 2 N2 - Originating from 25 selected intensive care units (ICUs) in North America, a total of 1,321 bacterial strains from blood, respiratory tract, urine and wound sites were processed at a central laboratory as part of the SENTRY Antimicrobial Surveillance Program (2001) to assess their occurrence rates and antimicrobial susceptibility profiles. The rank order of pathogens recovered was Staphylococcus aureus (24.1%), Pseudomonas aeruginosa (12.2%), Escherichia coli (10.1%), Klebsiella spp. (8.9%), Enterococcus spp. (7.2%), coagulase-negative staphylococci (7.0%) and Enterobacter spp. (7.0%). Although oxacillin resistance among S. aureus was 51.4%, no resistance was detected to vancomycin, linezolid and quinupristin/dalfopristin. The most active agents tested against P. aeruginosa were amikacin, cefepime, tobramycin, meropenem and piperacillin/tazobactam (3.1-13.0% resistance). Among agents tested against the Enterobacteriaceae, amikacin, cefepime, imipenem and meropenem showed greatest in vitro activity (0.0-3.4% resistance). Extended-spectrum beta-lactamase-producing phenotype rates were 11.2 and 16.2% in E. coli and Klebsiella spp., respectively. Linezolid was most active against enterococci (1.1% resistance; G2576U ribosomal mutation) whereas 28.4% of isolates were resistant to vancomycin. Cefepime and the carbapenems (imipenem or meropenem) for Gram-negative isolates and linezolid for Gram-positive isolates, provided the broadest spectrum of in vitro activity against contemporary ICU pathogens in North America. SN - 0924-8579 UR - https://www.unboundmedicine.com/medline/citation/15288308/Assessment_of_pathogen_occurrences_and_resistance_profiles_among_infected_patients_in_the_intensive_care_unit:_report_from_the_SENTRY_Antimicrobial_Surveillance_Program__North_America_2001__ DB - PRIME DP - Unbound Medicine ER -